Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer

Figure 5

External validation of the prognostic signature. (a–c) Kaplan–Meier survival analysis of the prognostic signature for predicting OS in the GSE84437, GSE26253, and TCGA cohorts. (d–f) The risk score distribution and the survival status of patients in the GSE84437, GSE26253, and TCGA cohorts.

(a)

(b)

(c)

(d)

(e)

(f)